Neurogene’s (NGNE) “Outperform” Rating Reiterated at William Blair

William Blair reissued their outperform rating on shares of Neurogene (NASDAQ:NGNE) in a research report sent to investors on Tuesday morning,RTT News reports. William Blair also issued estimates for Neurogene’s Q4 2024 earnings at ($1.04) EPS, FY2024 earnings at ($4.33) EPS, Q1 2025 earnings at ($1.08) EPS, Q2 2025 earnings at ($1.05) EPS, Q3 2025 earnings at ($1.09) EPS, Q4 2025 earnings at ($1.11) EPS and FY2025 earnings at ($4.32) EPS.

Other analysts have also issued reports about the stock. BMO Capital Markets reduced their price target on shares of Neurogene from $65.00 to $60.00 and set an “outperform” rating for the company in a research report on Tuesday, November 12th. Stifel Nicolaus increased their target price on shares of Neurogene from $44.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, November 12th. HC Wainwright restated a “buy” rating and set a $55.00 price target on shares of Neurogene in a report on Tuesday. Leerink Partners upped their price target on shares of Neurogene from $45.00 to $72.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 12th. Finally, Robert W. Baird lifted their price objective on Neurogene from $54.00 to $72.00 and gave the company an “outperform” rating in a research report on Tuesday, November 12th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Neurogene presently has a consensus rating of “Buy” and a consensus target price of $60.83.

Neurogene Price Performance

Shares of Neurogene stock opened at $15.59 on Tuesday. Neurogene has a 1 year low of $12.49 and a 1 year high of $74.49. The stock has a 50-day moving average price of $45.41 and a 200 day moving average price of $39.62.

Institutional Trading of Neurogene

A number of institutional investors and hedge funds have recently made changes to their positions in NGNE. Quest Partners LLC acquired a new stake in Neurogene in the 2nd quarter worth approximately $55,000. BNP Paribas Financial Markets raised its position in shares of Neurogene by 192.8% in the third quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company’s stock valued at $91,000 after purchasing an additional 1,429 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Neurogene in the first quarter worth $120,000. MetLife Investment Management LLC bought a new stake in shares of Neurogene during the 3rd quarter worth $254,000. Finally, Jane Street Group LLC bought a new stake in shares of Neurogene during the 3rd quarter worth $324,000. Institutional investors and hedge funds own 52.37% of the company’s stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.